Cover Image
市場調查報告書

勃起功能障礙:開發平台分析

Erectile Dysfunction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232812
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
勃起功能障礙:開發平台分析 Erectile Dysfunction - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 103 Pages
簡介

所謂勃起功能障礙(ED),是指男性不能維持性交必要的勃起的障礙,也稱為陽痿。易罹病素質包含有血緣和體重過剩、傷害、攝取毒品&酒精、藥物療法(抗憂鬱劑、抗組織胺藥物、高血壓治療藥、止痛藥、前列腺癌症治療藥等)等。

本報告提供全球各國的勃起功能障礙(ED)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

勃起功能障礙(ED)概要

治療藥的開發

  • 勃起功能障礙開發中產品:概要
  • 勃起功能障礙開發中產品:比較分析

各企業開發中的勃起功能障礙治療藥

大學/研究機關研究中的勃起功能障礙治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確階段的產品

勃起功能障礙治療藥:開發中的產品一覽(各企業)

勃起功能障礙治療藥:研究中的產品一覽(各大學/研究機關)

開發勃起功能障礙治療藥的企業

  • Acorda Therapeutics, Inc.
  • Apricus Biosciences, Inc.
  • Biopharm GmbH
  • Corridor Pharmaceuticals Inc.
  • Futura Medical Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Humanetics Corporation
  • IntelGenx Corp.
  • Mezzion Pharma Co. Ltd.
  • 田邊三菱製藥
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Pacific Therapeutics Ltd.
  • Palatin Technologies, Inc.
  • Pharmicell Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Suda Ltd
  • U.S. Stem Cell, Inc.
  • Yungjin Pharm. Co., Ltd.

勃起功能障礙:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 各標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (PDE-5 抑制劑 + 鹽酸toramadoru)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AdipoCell
  • alprostadil
  • AP-102
  • avanafil
  • BIO-300
  • BL-214
  • cimaglermin alfa
  • fadanafil
  • HCP-1302
  • HCP-1303
  • Immpocellgram
  • MED-2005
  • 硝化甘油
  • 心血管疾病、代謝異常、勃起功能障礙治療用 G蛋白偶聯受體Mas活性肽
  • 椎間盤退化性疾病、骨折、帕金森氏症、勃起功能障礙治療用合成蛋白質
  • 檸檬酸Sildenafil
  • 血管功能障礙、 PAH、勃起功能障礙治療用精氨酸抑制劑
  • 勃起功能障礙治療用 PDE5抑制劑
  • SUD-003
  • 女性的性功能障礙、勃起功能障礙治療用黑皮質素4受體工作合成肽
  • T-6932
  • tadalafil
  • TF-0092
  • TPN-171
  • TPN-729
  • TR-399
  • udenafil
  • VLFIA-330
  • YBH-1603

勃起功能障礙治療藥:開發中產品的最新趨勢

勃起功能障礙治療藥:開發暫停的產品

勃起功能障礙治療藥:開發中止的產品

勃起功能障礙相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9003IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 5, 4, 2, 2, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Erectile Dysfunction - Overview
  • Erectile Dysfunction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Erectile Dysfunction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
    • Apricus Biosciences Inc
    • Astellas Pharma Inc
    • Biolab Farmaceutica Ltda
    • Biopharm GmbH
    • Can-Fite BioPharma Ltd
    • Fabre-Kramer Pharmaceuticals Inc
    • Futura Medical Plc
    • Hanmi Pharmaceuticals Co Ltd
    • Humanetics Corp
    • IntelGenx Corp
    • Ion Channel Innovations LLC
    • iX Biopharma Ltd
    • Mezzion Pharma Co Ltd
    • Mitsubishi Tanabe Pharma Corp
    • Monosol Rx LLC
    • NAL Pharmaceuticals Ltd
    • Palatin Technologies Inc
    • Pharmicell Co Ltd
    • Suda Ltd
    • XuanZhu Pharma Co Ltd
    • Yungjin Pharm Co Ltd
  • Erectile Dysfunction - Drug Profiles
    • (tadalafil + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alprostadil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-ED - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fadanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FKK-01PD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HCP-1302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPED-2015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MED-2002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MED-2005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirabegron ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pVAX-hSlo - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sildenafil citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUD-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-6932 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TF-0092 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPN-729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TR-399 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLFIA-330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YBH-1603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones
    • Featured News & Press Releases
      • Feb 07, 2017: MonoSol Rx Receives FDA Acceptance of New Drug Application for Tadalafil PharmFilm
      • Jan 24, 2017: Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy
      • Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug - Fadanafil
      • Nov 28, 2016: MonoSol Rx Submits New Drug Application for Tadalafil PharmFilm
      • Nov 09, 2016: Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
      • Sep 13, 2016: iX Biopharma Announces Positive Results from Pivotal Study of Erectile Dysfunction Drug
      • Jul 27, 2016: VIVUS Files Lawsuit Against Hetero for Infringement of Stendra Patents
      • May 02, 2016: Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association Annual Meeting
      • Apr 11, 2016: Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
      • Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil
      • Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix
      • Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
      • Jan 27, 2015: Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
      • Dec 09, 2014: Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
      • Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Erectile Dysfunction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H1 2017
  • Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2017
  • Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H1 2017
  • Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2017
  • Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
  • Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2017
  • Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2017
  • Erectile Dysfunction - Pipeline by IntelGenx Corp, H1 2017
  • Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H1 2017
  • Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Erectile Dysfunction - Pipeline by Monosol Rx LLC, H1 2017
  • Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H1 2017
  • Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Suda Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
  • Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Erectile Dysfunction - Dormant Projects, H1 2017
  • Erectile Dysfunction - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Erectile Dysfunction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Erectile Dysfunction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top